Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

To facilitate commercialization of the ClotTriever system in Japan, Inari has entered into a distribution agreement with Medikit Co., Ltd., a market leading vascular medical device manufacturer ...

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a ...

Inari Medical Background Information (This ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep ...

Inari Medical, Inc. (NASDAQ ... The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and ...

It delivered a trailing four-quarter average earnings surprise of 24.77%. Inari Medical’s top-line growth is primarily driven by its ClotTriever and FlowTriever products that target patients with ...